NZ730490A - Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease - Google Patents

Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease Download PDF

Info

Publication number
NZ730490A
NZ730490A NZ730490A NZ73049015A NZ730490A NZ 730490 A NZ730490 A NZ 730490A NZ 730490 A NZ730490 A NZ 730490A NZ 73049015 A NZ73049015 A NZ 73049015A NZ 730490 A NZ730490 A NZ 730490A
Authority
NZ
New Zealand
Prior art keywords
ibs
antibodies
cdtb
vinculin
level
Prior art date
Application number
NZ730490A
Other languages
English (en)
Inventor
Christopher Chang
Mark Pimentel
Original Assignee
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cedars Sinai Medical Center filed Critical Cedars Sinai Medical Center
Publication of NZ730490A publication Critical patent/NZ730490A/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/205Assays involving biological materials from specific organisms or of a specific nature from bacteria from Campylobacter (G)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/06Gastro-intestinal diseases
    • G01N2800/065Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ730490A 2014-10-09 2015-10-08 Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease NZ730490A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462061877P 2014-10-09 2014-10-09
US201462085825P 2014-12-01 2014-12-01
PCT/US2015/054655 WO2016057772A1 (en) 2014-10-09 2015-10-08 Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease

Publications (1)

Publication Number Publication Date
NZ730490A true NZ730490A (en) 2021-07-30

Family

ID=55653760

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ730490A NZ730490A (en) 2014-10-09 2015-10-08 Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease

Country Status (16)

Country Link
US (2) US10132814B2 (enExample)
EP (1) EP3204771B1 (enExample)
JP (1) JP6784669B2 (enExample)
KR (1) KR102426541B1 (enExample)
CN (1) CN107003308B (enExample)
AU (1) AU2015330872B2 (enExample)
CA (1) CA2962493C (enExample)
ES (1) ES3028294T3 (enExample)
IL (1) IL251606B (enExample)
MX (1) MX384921B (enExample)
NZ (1) NZ730490A (enExample)
PL (1) PL3204771T3 (enExample)
PT (1) PT3204771T (enExample)
RU (1) RU2706361C2 (enExample)
SG (1) SG11201702395WA (enExample)
WO (1) WO2016057772A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11693009B2 (en) 2009-02-11 2023-07-04 Cedars-Sinai Medical Center Methods for detecting post-infectious irritable bowel syndrome
US12222352B2 (en) 2017-01-30 2025-02-11 Cedars-Sinai Medical Center Diagnosis of scleroderma

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX383424B (es) 2009-02-11 2025-03-14 Cedars Sinai Medical Center Anticuerpo contra toxina de distensión citoletal de campylobacter jejuni
KR102203568B1 (ko) 2012-09-17 2021-01-15 세다르스-신나이 메디칼 센터 장 및 방광의 운동 장애 및 섬유근육통의 진단 및 치료
AU2014331841B2 (en) 2013-10-09 2020-03-12 Cedars-Sinai Medical Center Diagnosis and treatment of irritable bowel syndrome and inflammatory bowel disease
ES3028294T3 (en) 2014-10-09 2025-06-18 Cedars Sinai Medical Center Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease
EP3913371A1 (en) 2020-05-18 2021-11-24 Neuroimmun GmbH Method and kit for diagnosting irritable bowel syndrome and for its relief through dietary interventions
CN113447649B (zh) * 2021-07-01 2022-04-19 浙江大学 一种检测抗粘着斑蛋白-IgG抗体的试剂盒

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5691151A (en) * 1994-10-07 1997-11-25 Regents Of University Of California Methods of screening for ulcerative colitis and crohn's disease by detecting VH3-15 autoantibody and panca
US7048906B2 (en) 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US6562629B1 (en) 1999-08-11 2003-05-13 Cedars-Sinai Medical Center Method of diagnosing irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth by detecting the presence of anti-saccharomyces cerivisiae antibodies (asca) in human serum
FR2806805A1 (fr) 2000-03-22 2001-09-28 Centre Nat Rech Scient SEQUENCE PEPTIDIQUES COMPRENANT UN OU PLUSIEURS MOTIFS DE LIAISON AUX PROTEINES DE LA FAMILLE Ena/VASP, ET LEURS UTILISATIONS
WO2003097854A2 (en) 2002-05-17 2003-11-27 Sugen, Inc. Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals
EP1578364A4 (en) 2002-09-16 2011-06-08 Genentech Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF ILLNESSES OF THE IMMUNE SYSTEM
US7595386B2 (en) 2003-01-24 2009-09-29 William Beaumont Hospital Methods and compositions for heat activated gene therapy using cytolethal distending toxin
US20050004155A1 (en) * 2003-04-08 2005-01-06 Boyd Thomas A. Use of methylnaltrexone to treat irritable bowel syndrome
JP4711963B2 (ja) 2003-09-15 2011-06-29 オクラホマ メディカル リサーチ ファウンデーション 炎症性疾患および自己免疫疾患を診断、治療および評価するためにサイトカインアッセイを用いる方法
CN102634524B (zh) 2003-12-05 2014-03-05 扶桑药品工业株式会社 细胞致死肿胀毒素及以其为目标的弯曲杆菌属细菌的检测
US20080085524A1 (en) 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
WO2008140484A2 (en) 2006-11-09 2008-11-20 Xdx, Inc. Methods for diagnosing and monitoring the status of systemic lupus erythematosus
DK2223121T3 (da) 2007-12-20 2012-10-22 Index Diagnostics Ab Publ Fremgangsmåde og kit til anvendelse ved differentiering mellem ibd og ibs og yderligere skelnen mellem ibd-sygdomstyper
WO2010045180A1 (en) 2008-10-13 2010-04-22 Metabolon, Inc. Biomarkers for inflammatory bowel disease and methods using the same
EP2370435B1 (en) 2008-11-24 2015-01-07 Cedars-Sinai Medical Center Antioxidant camptothecin derivatives and antioxidant antineoplastic nanospheres thereof
MX383424B (es) * 2009-02-11 2025-03-14 Cedars Sinai Medical Center Anticuerpo contra toxina de distensión citoletal de campylobacter jejuni
BRPI1008058A8 (pt) 2009-02-11 2018-03-27 Cedars Sinai Medical Center uso de antibióticos para reduzir a probabilidade de desenvolver síndrome do intestino irritável pós-infecciosa
FR2942541A1 (fr) 2009-02-25 2010-08-27 Assist Publ Hopitaux De Paris Procede de diagnostic d'une vascularite
RU2397178C1 (ru) * 2009-02-27 2010-08-20 Федеральное государственное учреждение науки "Центральный научно-исследовательский институт эпидемиологии" Федеральной службы по надзору в сфере защиты прав потребителей и благополучия человека Диагностическая тест-система в формате иммуночипа и способ серологической дифференциальной диагностики сифилиса
IT1400989B1 (it) 2010-07-13 2013-07-05 Segix Italia S R L Ora Istituto Biochimico Naz Savio S R L Forme di somministrazione orale a rilascio controllato di rifampicina per il trattamento di infezioni batteriche dell' apparato intestinale.
GB201017520D0 (en) 2010-10-15 2010-12-01 Sense Proteomic Ltd Biomarkers
JP5477671B2 (ja) 2012-02-28 2014-04-23 三菱マテリアル株式会社 サーミスタ用金属窒化物材料及びその製造方法並びにフィルム型サーミスタセンサ
KR102203568B1 (ko) 2012-09-17 2021-01-15 세다르스-신나이 메디칼 센터 장 및 방광의 운동 장애 및 섬유근육통의 진단 및 치료
AU2014331841B2 (en) 2013-10-09 2020-03-12 Cedars-Sinai Medical Center Diagnosis and treatment of irritable bowel syndrome and inflammatory bowel disease
ES3028294T3 (en) 2014-10-09 2025-06-18 Cedars Sinai Medical Center Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease
EP3573650A4 (en) 2017-01-30 2020-12-09 Cedars-Sinai Medical Center DIAGNOSIS OF SCLERODERMIA

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11693009B2 (en) 2009-02-11 2023-07-04 Cedars-Sinai Medical Center Methods for detecting post-infectious irritable bowel syndrome
US12222352B2 (en) 2017-01-30 2025-02-11 Cedars-Sinai Medical Center Diagnosis of scleroderma

Also Published As

Publication number Publication date
CA2962493C (en) 2023-01-10
CA2962493A1 (en) 2016-04-14
JP6784669B2 (ja) 2020-11-11
CN107003308A (zh) 2017-08-01
MX384921B (es) 2025-03-14
JP2017531801A (ja) 2017-10-26
MX2017004516A (es) 2017-10-12
RU2706361C2 (ru) 2019-11-18
EP3204771A4 (en) 2018-03-14
WO2016057772A1 (en) 2016-04-14
PT3204771T (pt) 2025-05-20
AU2015330872B2 (en) 2021-04-22
EP3204771B1 (en) 2025-03-12
SG11201702395WA (en) 2017-04-27
AU2015330872A1 (en) 2017-04-13
IL251606B (en) 2020-08-31
US20190187153A1 (en) 2019-06-20
KR20170067795A (ko) 2017-06-16
US10132814B2 (en) 2018-11-20
IL251606A0 (en) 2017-06-29
ES3028294T3 (en) 2025-06-18
PL3204771T3 (pl) 2025-07-28
CN107003308B (zh) 2020-02-11
US20160103136A1 (en) 2016-04-14
RU2017115663A3 (enExample) 2019-05-16
KR102426541B1 (ko) 2022-07-29
EP3204771A1 (en) 2017-08-16
RU2017115663A (ru) 2018-11-13
US10690679B2 (en) 2020-06-23

Similar Documents

Publication Publication Date Title
US10690679B2 (en) Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease
AU2015205899B2 (en) Methods for diagnosing irritable bowel syndrome
KR102259588B1 (ko) 과민성 장 증후군 및 염증성 장 질환의 진단 및 치료
US12222352B2 (en) Diagnosis of scleroderma
US20240159772A1 (en) Methods for Detecting and Treating Irritable Bowel Syndrome
HK1234824A1 (en) Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease
HK1234824B (en) Methods and systems for distinguishing irritable bowel syndrome from inflammatory bowel disease and celiac disease

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 OCT 2023 BY PAVIS PAYMENT GMBH

Effective date: 20221005

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 OCT 2024 BY BIRGIT KNAACK

Effective date: 20230929

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 OCT 2025 BY BIRGIT KNAACK

Effective date: 20240925

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 08 OCT 2026 BY CONSTANZE LINDHOFF

Effective date: 20251002